Skip to content
Men Under Microscope – Lifestyle
Home
Sample Page
Author:
Spero Therapeutics, Inc.
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
July 14, 2026
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
July 14, 2026
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
June 17, 2026
Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update
May 13, 2026
Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
May 5, 2026
Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026
March 18, 2026